Spero Therapeutics ( (SPRO) ) has released its Q4 earnings. Here is a breakdown of the information Spero Therapeutics presented to its investors.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing novel treatments for rare diseases and multi-drug resistant bacterial infections.
In its latest earnings report, Spero Therapeutics announced financial results for the fourth quarter and full year 2024, alongside updates on its clinical programs. The company is advancing its Phase 3 PIVOT-PO clinical trial for tebipenem HBr, an oral antibiotic for complicated urinary tract infections, and is analyzing data from its Phase 2 study of SPR720 for Nontuberculous Mycobacterial Pulmonary Disease. However, the SPR206 program for hospital-acquired pneumonia has been discontinued.
Financially, Spero reported a net loss of $20.9 million for Q4 2024, compared to a net income of $51.2 million in the same quarter of 2023. The company’s total revenue for the year decreased to $48.0 million from $103.8 million in 2023, primarily due to reduced collaboration revenue with partners like GSK and Pfizer. Despite increased research and development expenses, Spero’s cash reserves, bolstered by development milestones from GSK, are expected to fund operations into Q2 2026.
Strategically, Spero is focusing on the potential approval of tebipenem HBr, which could address a significant unmet need in treating complicated urinary tract infections. The company is also evaluating the future of its SPR720 program, given the high demand for new therapies in treating NTM-PD.
Looking ahead, Spero Therapeutics remains committed to advancing its clinical programs and optimizing its pipeline to meet critical healthcare needs, with a financial strategy aimed at sustaining operations through 2026.